natgillin/translations-raw huggingface dataset:
Transfer all the diluent to the vial.
Prenesite svo otapalo u bočicu.
Transfer diluent from syringe to the vial by pushing the plunger in all the way
Prenesite otapalo iz štrcaljke u bočicu guranjem klipa cijelom duljinom.
Transfer from GLP-1 receptor agonist therapy
Prijelaz s liječenja agonistom GLP-1 receptora
Transfer into seminal fluid: Seminal transfer of ribavirin has been studied.
Prijenos u sjemenu tekućinu: ispitivan je prijenos ribavirina u sjemenu tekućinu.
Transfer the appropriate volume of reconstituted solution of Metalyse into the syringe, based on the patient’s weight.
Prebacite odgovarajući volumen rekonstituirane otopine Metalysea u štrcaljku, ovisno o težini bolesnika.
Transfer the concentrate into a sterile, evacuated glass bottle or intravenous bag (PVC or non- PVC).
Prenesite koncentrat u sterilnu, praznu staklenu bocu ili intravensku vrećicu (PVC ili ne-PVC).
Transfer the entire contents (approximately 12.0 mL) of the resultant solution to an infusion bag immediately.
Odmah prenesite sav sadržaj (približno 12,0 ml) dobivene otopine u infuzijsku vrećicu.
Transfer the implant to the outlet of the catheter.
Prenesite implantat do otvora katetera.
Transfer the Ingelvac CircoFLEX vaccine into the vaccine bottle of Ingelvac MycoFLEX.
Prebacite cjepivo Ingelvac CircoFLEX u bočicu s cjepivom Ingelvac MycoFLEX.
Transfer the solution by pushing on the plunger slowly until all of the solution in the oral dosing syringe is transferred to a glass or cup for administration (e.g. if your doctor told you to dissolve two Kuvan tablets in 40 ml water and administer 30 ml to your child, you would have to use the 20 ml oral dosing syringe two times to draw up 30 ml (e.g.
Prenesite otopinu tako što ćete polako potiskivati klip sve dok ne istisnete svu otopinu iz oralne štrcaljke za doziranje u čašu ili šalicu za primjenu (npr. ako Vam je liječnik rekao da otopite dvije tablete Kuvana u 40 ml vode i djetetu date 30 ml, morat ćete dvaput uporabiti oralnu štrcaljku za doziranje od 20 ml kako biste izvukli 30 ml (npr.
Transfer the suspension into the diluent (Do not use if cloudy).
Prenesite suspenziju u razrjeđivač (Ne koristite ako je mutna).
Transfer the suspension into the diluent (Do not use if cloudy).
Prenesite suspenziju u razrjeđivač (Ne primjenjivati ako je mutna).
Transfer the suspension into the diluent.
Prenesite suspenziju u razrjeđivač.
transfer to
CANCIDAS dodan u
transfer to
CANCIDAS koji
Transfer to Xultophy from doses of basal insulin < 20 and > 50 units has not been studied.
Prelazak s doza bazalnog inzulina < 20 i > 50 jedinica na lijek Xultophy nije ispitivan.
transferase increased
organskih
transferase increased
povišena alkalna
Transferring a patient to another type or brand of insulin
Prebacivanje bolesnika na drugu vrstu ili inzulin drugog proizvođača
Transferring patients from immediate-release cysteamine bitartrate hard capsules
Prelaženje bolesnika s tvrdih kapsula s trenutačnim oslobađanjem cisteamin bitartrata
Transformation at 60 months, n/N (%)
Transformacija u 60. mjesecu, n/N (%)
Transformation to AP/BPf On-treatment transformation, n
Tranformacija tijekom liječenja, n
Transformation to leukaemia or myelodysplastic syndrome
Napredovanje u leukemiju ili mijelodisplastični sindrom
Transfusion Avoidance during treatment (%)
Izbjegnuta transfuzija tijekom liječenja (%)
Transfusion Independence (≥ 182 days) #
Neovisnost o transfuziji (≥ 182 dana)#
Transfusion Independence (≥ 56 days) #
Neovisnost o transfuziji (≥ 56 dana)#
Transfusion of 2 or more units of packed red blood cells or whole
Transfuzija 2 ili više jedinica koncentrata eritrocita ili pune krvi
Transfusion of 4 or more units of blood over a 48 hour period
Transfuzija 4 ili više jedinica krvi u razdoblju od 48 sati
Transfusion reaction, Fractures*, Rigors*, Face injury, Joint injury*, Burns, Laceration, Procedural pain, Radiation injuries*
Reakcije transfuzije, lomovi*, tresavica*, ozljeda lica, ozljeda zgloba*, opekline, laceracija, proceduralna bol, radijacijske ozljede
Transfusion Related Acute Lung Injury (TRALI)
Akutna ozljeda pluća povezana s transfuzijom
Transfusion-related acute lung injury
akutna ozljeda pluća povezana s transfuzijom
Transfusion-related acute lung injury (TRALI)
Akutna ozljeda pluća povezana s transfuzijom
Transfusions of cryoprecipitate, fibrinogen, fresh frozen plasma and platelets should be considered with clinical and laboratory reassessment after each administration.
Treba razmotriti transfuziju krioprecipitata, fibrinogena, svježe zamrznute plazme i trombocita s ponovnim kliničkim i laboratorijskim procjenama nakon svake primjene.
Transient amnesia5
prolazna amnezija5
Transient antibodies against Leishmania detected by immunofluorescence antibody test (IFAT) may appear after vaccination.
Kratkotrajna protutijela na lišmaniju mogu po cijepljenju biti otkrivena imunofluorescentnim testom na protutijela (IFAT).
Transient apathy and fever (above 39.5 °C) may occur.
Mogu se pojaviti prolazna apatija i vrućica (iznad 39,5 °C).
Transient apathy and hyperthermia (above 39.5 °C) may occur.
Mogu se pojaviti prolazna apatija i hipertermija (iznad 39,5 °C).
Transient blindness, lens subluxation*, night blindness, scotoma, pupillary reflex impaired, visual field defect, diplopia, hyphaema, miosis, pupils unequal, corneal abrasion, anterior chamber inflammation, eye inflammation, conjunctival irritation
Prolazna sljepoća, subluksacija leće*, noćno sljepilo, skotom, oštećeni refleks zjenice, defekt vidnog polja, diplopija, hifema, mioza, nejednake zjenice, abrazija rožnice, upala u prednjoj očnoj sobici, upala oka, nadražaj konjunktive.
Transient blindness, lens subluxation*, night blindness, scotoma, pupillary reflex impaired, visual field defect, diplopia, hyphaema, miosis, pupils unequal, corneal abrasion, anterior chamber inflammation, eye inflammation, conjunctival irritation
Prolazna sljepoća, subluksacija leće*, noćno sljepilo, skotom, oštećenje refleksa zjenice, defekt vidnog polja, diplopija, hifema, mioza, nejednake zjenice, abrazija rožnice, upala u prednjoj očnoj sobici, upala oka, nadražaj konjunktive.
Transient but fully reversible infertility in male rats was associated with migalastat treatment at all doses assessed.
Prolazna, ali potpuno reverzibilna neplodnost u mužjaka štakora bila je povezana s liječenjem migalastatom pri primjeni svih ispitivanih doza.
Transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).
Zabilježena je pojava prolazne zimice (u 3% bolesnika), vrućice (u 2% ) ili bolesti nalik gripi (u 1% bolesnika) nekoliko sati nakon primjene doze.
transient corneal opacity
prolazna zamućenost rožnice
Transient cosmetic effects such as wet hair and a white dry residue may occur at the application site and may persist up to 7 days; however, these effects are usually not noticeable after 48 hours.
Prolazni kozmetički učinci, kao što su mokra dlaka i suh, bijeli talog, mogu se javiti na mjestu primjene i mogu biti prisutni do 7 dana, međutim ti učinci se obično ne primjećuju nakon 48 sati.
Transient ECG changes such as T-wave flattening, S-T segment depression and benign arrhythmias are not considered mandatory indications for the cessation of Myocet therapy.
Prolazne promjene u EKG-u poput zaravnjenja T-vala, pada u S-T segmentu i benignih aritmija ne smatraju se obveznim indikacijama za prekid terapije Myocetom.
Transient effects on components of innate immunity (i.e., neutrophils, macrophages, NK cells)
Prolazne učinke na komponente urođenog imuniteta (tj. neutrofile, makrofage, NK stanice)
Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), bilirubin and white blood cell count may occur with sevoflurane, as with the use of other halogenated anaesthetic agents.
Kod primjene sevoflurana, kao i primjene drugih halogeniranih anestetika, mogu se javiti prolazna povećanja vrijednosti aspartat aminotransferaze (AST), alanin aminotransferaze (ALT), laktat dehidrogenaze (LDH), bilirubina i broja bijelih krvnih stanica.
Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), bilirubin and white blood cell counts may occur with sevoflurane, as with the use of other halogenated anaesthetic agents.
Kod primjene sevoflurana, kao i primjene drugih halogeniranih anestetika, mogu se javiti prolazna povećanja vrijednosti aspartat aminotransferaze (AST), alanin aminotransferaze (ALT), laktat dehidrogenaze (LDH), bilirubina i broja bijelih krvnih stanica.
Transient elevations of transaminases at the initiation of cholic acid treatment have been observed and do not indicate the need for a dose reduction if GGT is not elevated and if serum bile acid levels are falling or in the normal range.
Uočena su prolazna povišenja vrijednosti transaminaza u početnoj fazi liječenja kolnom kiselinom, ali to nije indikacija za smanjivanje doze ako razina GGT-a nije povišena i ako se razine žučne kiseline u serumu smanjuju ili se nalaze u rasponu normalnih vrijednosti.
Transient episodes of hypertonia and/or severe muscular weakness that prevent voluntary movements may occur at any time during treatment.
Prolazne epizode hipertonije i/ili teška mišićna slabost koje sprječavaju voljne pokrete mogu se javiti bilo kad tijekom lječenja.
transient flu-like symptoms, such as aching muscles, generally feeling unwell and sometimes with fever usually at the start of treatment, taste disturbance.
prolazni simptomi nalik gripi, kao što su bolovi u mišićima, opće loše stanje, a katkad i vrućica, obično na početku liječenja, promjena osjeta okusa.
Transient hypertension has been observed primarily during the loading dose in association with the peripheral vasoconstrictive effects of dexmedetomidine and a loading dose is not recommended.
Prolazna je hipertenzija zabilježena prvenstveno tijekom davanja udarne doze, vezano za periferne vazokonstrikcijske učinke deksmedetomidina pa se davanje udarne doze ne preporučuje.
Transient increase in serum creatinine may be greater in patients with underlying impaired renal function.
Prolazni porast kreatinina u serumu može biti veći u bolesnika koji imaju predležeću oštećenu funkciju bubrega.
Transient increase in serum creatinine may be greater in patients with underlying impaired renal function.
Prolazni porast kreatinina u serumu može biti veći u bolesnika s podležećim oštećenjem funkcije bubrega.
Transient increase in serum creatinine may be greater in patients with underlying impaired renal function.
prolazno povećanje serumskog kreatinina može biti veće u bolesnika s podležećim oštećenjem bubrega
transient increase in serum IgM levels3
prolazno povećanje serumske razine IgM-a3
Transient inhibition of P-gp by
Prolazna inhibicija P-gp putem
Transient ischaemic attack
cerebrovaskularni incident* tranzitorna ishemijska ataka
Transient ischaemic attack
tranzitorna ishemična ataka
Transient ischaemic attack, Seizure*,
tranzitorna ishemijska ataka,
Transient ischaemic attack, Seizure*, Seizure recurrence*, Syncope
napadaji*, ponavljanje napadaja*, sinkopa
transient ischaemic attacks
prolazni ishemični poremećaj
Transient ischaemic attacks and cerebrovascular accident
Tranzitorna ishemijska ataka i cerebrovaskularni inzult
Transient ischemic attack, cerebral vascular accident
prolazna ishemijska ataka, cerebrovaskularni inzult
Transient local injection site reactions, which are restricted to a slight swelling (< 2 cm diameter), may uncommonly occur and disappear within 1 day.
Prolazne lokalne reakcije na mjestu injekcije, koje su ograničene na blago oticanje ( < 2 cm dijametralno) rijetko se mogu pojaviti te nestaju u roku od jednog dana.
Transient local injection site reactions, which are restricted to a slight swelling (< 2 cm diameter), may uncommonly occur and disappear within 1 day.
Prolazne lokalne reakcije na mjestu injiciranja, koje su ograničene na blago oticanje (< 2 cm dijametralno) se mogu pojaviti te nestati u roku od jednog dana.
Transient local reactions at the application site (erythema and/or pruritus) can occur in very rare cases (less than 1 in 10,000 animals).
Prolazne lokalne reakcije na mjestu aplikacije (crvenilo i/ili svrbež) se mogu javiti u vrlo rijetkim slučajevima (manje od 1 na 10000 životinja).
Transient local reactions at the application site (erythema and/or pruritus) can occur in very rare cases (less than 1 in 10,000 animals).
Prolazne lokalne reakcije na mjestu aplikacije (crvenilo, i/ili svrbež) se mogu javiti u vrlo rijetkim slučajevima (manje od 1 na 10000 životinja).
Transient local reactions at the injection site may occur after vaccination mainly in the form of a hard, warm and sometimes painful swelling (diameter up to 10 cm).
Prolazne lokalne reakcije na mjestu ubrizgavanja nakon cijepljenja se pojavljuju u obliku tvrde, tople i ponekad bolne otekline (promjera do 10 cm).
Transient local reactions may occur after the administration of one dose of vaccine.
Nakon primjene jedne doze cjepiva mogu se pojaviti prolazne lokalne reakcije.
Transient loss of consciousness, paraesthesia
prolazan gubitak svijesti, parestezija
transient low blood pressure; pain and swelling of the joints, similar to gout.
prolazno niski krvni tlak; bol i oticanje zglobova, nalik na giht.
Transient muscular tremors, incoordination and depression were occasionally observed when the veterinary product was administered at overdoses of up to 5 times the recommended dose.
Prolazan mišićni tremor, nekoordiniranost i depresija su povremeno uočeni kada je veterinarsko- medicinski proizvod primijenjen u dozi 5 puta većoj od preporučene.
Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.
Uočena je prolazna midrijaza, slinjenje, povraćanje i prolazno frekventnije disanje.
Transient ocular changes (see Clinical experience).
prolazne očne promjene (vidjeti Kliničko iskustvo)
Transient platelet response was defined as weekly platelet count ≥ 50 x 109/l for 4 or more times during study weeks 2-25 but without durable platelet response.
Prolazni odgovor trombocita definiran je tjednim brojem trombocita ≥ 50 x 109/l, i to u 4 ili više puta od 2 do 25 tjedna ispitivanja, ali bez dugotrajnog odgovora trombocita.
Transient profound oligospermia has been reported following exposure to 6–mercaptopurine in combination with corticosteroids.
Prolazna izrazita oligospermija zabilježena je nakon izloženosti 6-merkaptopurinu u kombinaciji s kortikosteroidima.
Transient replicons carrying NS5A or NS5B from patient isolates.
Prolazni replikoni koji nose NS5A ili NS5B iz izolata pacijenata.
Transient skin redness, itching or other signs of discomfort at the application site have been reported rarely and usually disappear without any treatment and within 24 hours after using the medicine.
Prolazno crvenilo kože, svrbež i drugi znakovi nelagode na mjestu primjene prijavljeni su rijetko i obično nestaju bez liječenja unutar 24 sata nakon upotrebe proizvoda.
Transient swelling at the injection site was commonly reported in clinical studies following subcutaneous administration in cattle.
Prolazno oticanje na mjestu uboda opaženo je u kliničkim ispitivanjima nakon subkutane primjene u goveda.
Transient swelling at the injection site was observed in clinical studies following intramuscular administration in pigs.
Prolazno oticanje opaženo je u kliničkim ispitivanjima nakon intramuskularne primjene u svinja.
transient symptoms as in an acute-phase response (myalgia, malaise and rarely, fever), typically in association with initiation of treatment†
prolazni simptomi kao što su odgovor akutne faze (mialgija, malaksalost i rijetko vrućica), tipično povezani s početkom liječenja
Transient thrombocytopenia
Prolazna trombocitopenija
Transient thrombocytopenia (platelets < 100 x 109/L) following filgrastim administration and leukapheresis was observed in 35 % of subjects studied.
Prolazna trombocitopenija (trombociti < 100 x 109/l) nakon primjene filgrastima i nakon leukafereze zabilježena je u 35 % ispitanika.
Transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim administration and leukapheresis was observed in 35% of subjects studied.
Prolazna trombocitopenija (trombociti <100 x 109/l) nakon primjene filgrastima i leukafereze zabilježena je u 35% ispitanika.
Transient thrombocytopenia.
Prolazna trombocitopenija.
Transient visual loss occurring during or within 2 hours of infusion.
Nepoznato: prolazan gubitak vida koji se javlja tijekom ili do 2 sata nakon infuzije
Transient visual loss occurring during or within two hours of infusion
prolazan gubitak vida koji se javlja tijekom ili do 2 sata nakon infuzije
Transient,
Prolazni
Transient,
Prolazni asimptomatski
Transient, asymptomatic
Prolazni asimptomatski
Transient, asymptomatic elevations of hepatic aminotransfer ases (ALT, AST), especially in early treatment (see section 4.4)
prolazni asimptomatski porasti razina aminotransferaza jetre (ALT, AST), osobito na početku liječenja (vidjeti dio 4.4)
Transient, asymptomatic elevations of hepatic aminotransferases
prolazni asimptomatski porasti razina aminotransferaza jetre (ALT, AST), osobito na početku liječenja (vidjeti dio 4.4)
Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST), especially in early treatment (see section 4.4)
prolazni asimptomatski porasti razina aminotransferaza jetre (ALT, AST), osobito na početku liječenja (vidjeti dio 4.4)
Transient, asymptomatic elevations of hepatic aminotransferases , alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Često je uočen prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza, alanin transferaze (ALT) i aspartat transferaze (AST), osobito u ranoj fazi liječenja.
Transient, asymptomatic elevations of hepatic aminotransferases , alanine transferase (ALT), aspartatetransferase (AST) have been seen commonly, especially in early treatment.
Često je uočen prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza, alanin transferaze (ALT) i aspartat transferaze (AST), osobito u ranoj fazi liječenja.
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Često je uočen prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza, ALT i AST, osobito u ranoj fazi liječenja.
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartatetransferase (AST) have been seen commonly, especially in early treatment.
Često su uočen prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza, alanin transferaze (ALT) i aspartat transferaze (AST), osobito u ranoj fazi liječenja.
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartatetransferase (AST) have been seen commonly, especially in early treatment.
Često su uočen prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza, alanin transferaze (ALT) i aspartat transferaze (AST), osobito u ranoj fazi liječenja.
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartatetransferase (AST) have been seen commonly, especially in early treatment.
Često su uočeni prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza, alanin transferaze (ALT) i aspartat transferaze (AST), osobito u ranoj fazi liječenja.
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartatetransferase (AST) have been seen commonly, especially in early treatment.
Često su uočeni prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza, alanin transferaze (ALT) i aspartat transferaze (AST), osobito u ranoj fazi liječenja.
Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen commonly, especially in early treatment.
Prolazna, asimptomatska povišenja jetrenih aminotransferaza, ALT-a, AST-a često su bila uočena, pogotovo na početku liječenja.
Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen commonly, especially in early treatment.
Često je uočen prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza, ALT i (AST, osobito u ranoj fazi liječenja.
Transient, asymptomatic elevations of hepaticaminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Često su uočeni prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza, ALT i AST, osobito u ranoj fazi liječenja.
Transient, minor increases in alkaline phosphatase, LDH, SGOT (serum glutamic oxaloacetic transaminase) and uric acid have been reported in normal donors receiving filgrastim; these were without clinical sequelae.
U zdravih davatelja koji su primali filgrastim bilo je prijava prolaznog i slabog povišenja alkalne fosfataze, LDH, AST i mokraćne kiseline; to nije imalo nikakvih kliničkih posljedica.
Transition from other insulins to ABASAGLAR
Prijelaz s drugih inzulina na lijek ABASAGLAR
Transition from other insulins to Toujeo
Prijelaz s drugih inzulina na Toujeo
Transitory hyperthermia was observed, as well as a significant rise in lymphocytes and a significant decrease in thrombocytes and segmented neutrophils.
Primjećena je prolazna hipertermija, kao i značajan porast u broju limfocita i značajno smanjenje broja trombocita i segmentiranih neutrofila.
Transitory scratching, erythema or hair loss at the application site may occur.
Može doći do prolaznog grebanja, eritema ili gubitaka dlake na mjestu primjene.
Transitory scratching, erythema or hair loss at the application site may occur.
Prolazno grebanje, eritem ili gubitak dlake se može pojaviti na mjestu primjene.
Translarna 1,000 mg granules for oral suspension
Translarna 1000 mg granule za oralnu suspenziju
Translarna 1,000 mg granules for oral suspension ataluren
Translarna 1000 mg granule za oralnu suspenziju ataluren
TRANSLARNA 10 mg/kg, 10 mg/kg, 20 mg/kg (N=57) Placebo (N=57)
TRANSLARNA 10, 10, 20 mg/kg (N=57)
Translarna 125 mg granules for oral suspension
Translarna 125 mg granule za oralnu suspenziju
Translarna 125 mg granules for oral suspension Translarna 250 mg granules for oral suspension Translarna 1000 mg granules for oral suspension Ataluren
Translarna 125 mg granule za oralnu suspenziju Translarna 250 mg granule za oralnu suspenziju Translarna 1000 mg granule za oralnu suspenziju ataluren
Translarna 250 mg granules for oral suspension
Translarna 250 mg granule za oralnu suspenziju
Translarna can only be obtained with a prescription and treatment should be started by a specialist doctor experienced in the management of Duchenne/Becker muscular dystrophy.
Translarna se izdaje samo na liječnički recept, a liječenje treba započeti liječnik specijalist s iskustvom u tretmanu Duchenneve/Beckerove mišićne distrofije.
Translarna has been given ‘conditional approval’.
Za lijek Translarna izdano je „uvjetno odobrenje”.
Translarna has been studied in one main study involving 174 patients with Duchenne muscular dystrophy who were able to walk, where two doses of Translarna (40 mg/kg daily and 80 mg/kg daily) were compared with placebo (a dummy treatment).
Translarna je ispitan u jednom glavnom ispitivanju koje je obuhvatilo 174 bolesnika oboljelih od Duchenneove mišićne distrofije koji mogu hodati, u kojem su dvije doze lijeka Translarna (40 mg/kg dnevno i 80 mg/kg dnevno) uspoređene s placebom (prividnim liječenjem).
Translarna is available as granules (100, 250 and 1,000 mg) to be taken by mouth after mixing them with liquid or semi-solid food (such as yogurt).
Lijek Translarna dostupan je u granulama (100, 250 i 1.000 mg) koje se uzimaju kroz usta nakon što se pomiješaju s tekućinom ili polukrutom hranom (poput jogurta).
Translarna is available in 3 strengths, each containing 125 mg, 250 mg and 1,000 mg of the active substance, called ataluren.
Lijek Translarna dostupan je u 3 jačine, svaka sadrži 125 mg, 250 mg i 1000 mg djelatne tvari naziva ataluren.